Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05224089 · ClinicalTrials.gov registry record · Phase 4
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
A Phase 4 study of Bowel Disease, sponsored by Hartford Hospital.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 114
- Enrollment target
- 1
- Study location
NCT05224089 is a Phase 4 study of Bowel Disease that is actively recruiting participants, run by Hartford Hospital. The registered enrollment target is 114 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05224089, a Phase 4 study of Bowel Disease, is actively recruiting participants, sponsored by Hartford Hospital.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 114 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will be a single center, prospective triple blinded randomized controlled study, comparing the use of liposomal bupivacaine (Exparel) to regular bupivacaine with adjuncts in bilateral mid-abdominal transverse abdominis plane (TAP) blocks for patients undergoing laparoscopic colectomy procedures.
Conditions Studied
Interventions
- DRUG Liposomal Bupivicaine/Bupivacaine Admixture
- DRUG Bupivacaine HCL
Study Locations (1)
Connecticut
- Hartford Hospital - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2022-04-27 |
| Est. Completion | 2026-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05224089
The ClinicalTrials.gov registry entry for NCT05224089 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hartford Hospital, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bowel Disease appearing as the primary indexed condition, and to 2 interventions - of which Liposomal Bupivicaine/Bupivacaine Admixture is the first listed.
NCT05224089 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT05224089 about?
NCT05224089 is a clinical study titled "Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy". This study will be a single center, prospective triple blinded randomized controlled study, comparing the use of liposomal bupivacaine (Exparel) to regular bupivacaine with adjuncts in bilateral mid-abdominal transverse abdominis plane (TAP) blocks for patients undergoing laparoscopic colectomy proc...
What is the current status of trial NCT05224089?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 114 participants. The study started on 2022-04-27. Estimated completion is 2026-02.
What conditions does trial NCT05224089 study?
This clinical trial studies the following conditions: Bowel Disease.
What interventions are being tested in trial NCT05224089?
The interventions under investigation include: Liposomal Bupivicaine/Bupivacaine Admixture (DRUG), Bupivacaine HCL (DRUG).
Who is sponsoring clinical trial NCT05224089?
This trial is sponsored by Hartford Hospital, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05224089 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.